# Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19

> **NCT04327505** · PHASE2,PHASE3 · TERMINATED · sponsor: **Karolinska Institutet** · enrollment: 34 (actual)

## Conditions studied

- SARS (Severe Acute Respiratory Syndrome)
- Cytokine Storm
- ARDS, Human
- COVID-19
- Sars-CoV2
- Acute Respiratory Failure

## Interventions

- **DRUG:** Hyperbaric oxygen

## Key facts

- **NCT ID:** NCT04327505
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-03
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-01
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Futility, change of disease due to virus mutations and/or vaccination
- **Last updated:** 2023-01-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327505, "Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04327505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*